{
    "organizations": [],
    "uuid": "7fd973dfc22ba805f303213fab111d39fd494d2d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-provides-update-on-phase-3/brief-pfizer-provides-update-on-phase-3-trial-of-axitinib-idUSASC09VG5",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Provides Update on Phase 3 Trial of Axitinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10, 2018 / 6:39 PM / in 3 minutes BRIEF-Pfizer Provides Update on Phase 3 Trial of Axitinib Reuters Staff 1 Min Read \nApril 11 (Reuters) - Pfizer Inc: \n* PFIZER PROVIDES UPDATE ON PHASE 3 TRIAL OF AXITINIB AS ADJUVANT TREATMENT FOR PATIENTS AT HIGH RISK OF RENAL CELL CARCINOMA RECURRENCE AFTER SURGERY \n* IN TRIAL, NO NEW SAFETY SIGNALS WERE OBSERVED, AND SAFETY PROFILE WAS CONSISTENT WITH KNOWN PROFILE OF INLYTA IN ADVANCED RCC \n* INDEPENDENT COMMITTEE FOR PHASE 3 ATLAS TRIAL OF INLYTA RECOMMENDED STOPPING TRIAL AT A PLANNED INTERIM ANALYSIS DUE TO FUTILITY \n* DMCâ€™S RECOMMENDATION BASED ON AXITINIB STUDY FAILING TO DEMONSTRATE A CLEAR IMPROVEMENT IN PRIMARY ENDPOINT \n* STUDIES EVALUATING INLYTA IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR VARIETY OF ADVANCED STAGE CANCERS, INCLUDING RCC, TO CONTINUE \n* WILL CONDUCT ADDITIONAL ANALYSES ON DATA FROM AXITINIB STUDY Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T21:37:00.000+03:00",
    "crawled": "2018-04-10T21:49:43.028+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "minute",
        "provides",
        "update",
        "phase",
        "trial",
        "axitinib",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "provides",
        "update",
        "phase",
        "trial",
        "axitinib",
        "adjuvant",
        "treatment",
        "patient",
        "high",
        "risk",
        "renal",
        "cell",
        "carcinoma",
        "recurrence",
        "surgery",
        "trial",
        "new",
        "safety",
        "signal",
        "observed",
        "safety",
        "profile",
        "consistent",
        "known",
        "profile",
        "inlyta",
        "advanced",
        "rcc",
        "independent",
        "committee",
        "phase",
        "atlas",
        "trial",
        "inlyta",
        "recommended",
        "stopping",
        "trial",
        "planned",
        "interim",
        "analysis",
        "due",
        "futility",
        "dmc",
        "recommendation",
        "based",
        "axitinib",
        "study",
        "failing",
        "demonstrate",
        "clear",
        "improvement",
        "primary",
        "endpoint",
        "study",
        "evaluating",
        "inlyta",
        "combination",
        "immune",
        "checkpoint",
        "inhibitor",
        "variety",
        "advanced",
        "stage",
        "cancer",
        "including",
        "rcc",
        "continue",
        "conduct",
        "additional",
        "analysis",
        "data",
        "axitinib",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}